Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

被引：0
|
作者：
Moshe C. Ornstein
Laura S. Wood
机构：
[1] Cleveland Clinic,Hematology and Medical Oncology
[2] Cleveland Clinic,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adverse event; Axitinib; Combination; First-line; Immune checkpoint inhibitor; Renal cell carcinoma; Therapy management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3599 / 3609
页数：10
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions
    Tung, Iris
    Sahu, Arvind
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
    Fontes-Sousa, Mario
    Calvo, Emiliano
    CANCER TREATMENT REVIEWS, 2022, 105
  • [23] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [24] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [25] The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma
    Parreira, Sara
    Burns, Kathleen
    Moldawer, Nancy
    Zomordian, Nazy
    Bandali, Nesan
    Virdee, Kiran
    Walsh, Meghara
    Kelly, Daniel
    Rao, Dharanija
    Teresi, Rosemary
    Wood, Laura S.
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [26] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
    Li, Ying
    Ji, Yanyan
    Shen, Lin
    Yin, Xudong
    Huang, Tianyu
    Deng, Bin
    Guo, Hong
    Wu, Yunjiang
    Chen, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma
    Klaassen, Zachary
    Satkunasivam, Raj
    Wallis, Christopher J. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2581 - 2582
  • [29] Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma
    Ruan, Minghao
    Yang, Cheng
    Zhao, Jing
    Zhi, Kangkang
    Feng, Xiaochen
    Zhang, Jin
    Jin, Riming
    Li, Yao
    Wu, Dong
    Liu, Hui
    Sun, Wen
    Wang, Ruoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma
    Flippot, Ronan
    Gorgeu, Violaine
    Pujalte, Marc
    Colomba, Emeline
    Alves, Carolina
    Cerbone, Luigi
    Carril, Lucia
    Derosa, Lisa
    Escudier, Bernard
    Albiges, Laurence
    BULLETIN DU CANCER, 2022, 109 (02) : S31 - S38
12345